Biocon, HCG hospitals team up to fight cervical cancer
10 December 2009
Biocon and the HCG group of hospitals today announced a partnership to conduct a study on the use of Bicon's humanised monoclonal antibody `BIOMAb EGFR'' for the treatment of cervical cancer.
`BIOMAb EGFR' is approved for the treatment of head and neck cancers in India.
"This unique molecule would take healthcare for cervical cancer patients to a new threshold," a Biocon release said.
Bangalore-based Biocon said the study would be conducted for six years in various centers of HCG across the country, with participating centers in Bangalore, Mysore, Vijayavada, Ranchi, Cuttack and Nashik.
Several eminent oncologists will evaluate the results and the study will be in compliance to ICH-GCP guidelines, it added.
"This partnership is in light of the unmet need for an effective treatment option for the large number of cervical cancer patients in our country. I see this collaborative model of Biocon's unique humanised MAb and HCG's state-of-the-art facilities as a big step towards developing India as a global destination for translational research and cutting edge clinical trials." said Kiran Mazumdar Shaw, MD, Biocon Ltd.